Home › Therapeutic areas › Immunology › Rheumatoid Arthritis

Rheumatoid Arthritis (13 companies)

Companies with an active program in Rheumatoid Arthritis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.36B 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 1 Phase 2 $13.2M 4
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
EVMN Evommune DermatologyImmunology+1 1 Phase 2 $290M 6
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
IMVT Immunovant ImmunologyNeurology Rare 1 Phase 3 $6.87B 4
INSM Insmed CardiovascularImmunology+3 Rare 1 Approved $26.7B 15
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $1.07B 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
NKTX Nkarta ImmunologyNeurology+1 Rare 1 Phase 1 $89.6M 8
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 1 NDA Submitted $1.88B 11